Advertisement

Journal of Gastroenterology

, Volume 48, Issue 3, pp 322–332 | Cite as

Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells

  • Camilla Kappe
  • Cesare Patrone
  • Jens J. Holst
  • Qimin Zhang
  • Åke Sjöholm
Original Article—Alimentary Tract

Abstract

Background

Metformin is the most frequently prescribed drug for treatment of type 2 diabetes. It improves insulin resistance and glycemia by reducing hepatic gluconeogenesis. In addition, diabetic patients on metformin therapy have elevated levels of the insulinotropic hormone glucagon-like peptide-1 (GLP-1) and metformin has been shown to regulate the expression of the GLP-1R in the pancreas.

Methods

We have studied the direct long-term effects of metformin on apoptosis, and function of GLP-1-secreting L cells in vitro, using the murine GLUTag cell line as a model. The apoptosis of GLUTag cells was detected by DNA-fragment assay and caspase-3 activity determination. GLP-1 secretion was determined using ELISA and the expression of proglucagon mRNA was assessed by reverse transcription polymerase chain reaction. The activation of intracellular messengers was determined using western blotting.

Results

Metformin significantly decreased lipotoxicity-induced apoptosis in conjunction with increased phosphorylated AMPK. Metformin also countered the JNK2 activation evoked by lipotoxicity. In addition, long-term metformin treatment stimulated GLP-1 secretion.

Conclusion

This study demonstrates that metformin protects against lipoapoptosis (possibly by blocking JNK2 activation), and enhances GLP-1 secretion from GLP-1-producing cells in vitro. These direct effects of the drug might explain the elevated plasma GLP-1 levels seen in diabetic patients on chronic metformin therapy. The findings may also be harnessed to therapeutic advantage in efforts aiming at enhancing endogenous GLP-1 secretion in type 2 diabetic patients.

Keywords

Glucagon-like peptide-1 Gluconeogenesis Insulinotropic Lipotoxicity L cell 

Abbreviations

AMPK

AMP-activated protein kinase

JNK2

c-Jun N-terminal kinase

GLP-1

Glucagon-like peptide-1

PKA

Protein kinase A

PKC

Protein kinase C

Notes

Acknowledgments

This work was generously supported financially by Stiftelsen Olle Engkvist Byggmästare, an EFSD/Amylin research grant, and Stiftelsen Sigurd and Elsa Goljes Minne.

Conflict of interest

No conflicts of interest, financial or otherwise, are declared by the authors.

References

  1. 1.
    Meetoo D, McGovern P, Safadi R. An epidemiological overview of diabetes across the world. Br J Nurs. 2007;16(16):1002–7.PubMedGoogle Scholar
  2. 2.
    Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest. 2007;117(1):24–32.PubMedCrossRefGoogle Scholar
  3. 3.
    Meier JJ, Nauck MA. Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes Metab Res Rev. 2005;21(2):91–117.PubMedCrossRefGoogle Scholar
  4. 4.
    Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50(3):609–13.PubMedCrossRefGoogle Scholar
  5. 5.
    Rutter GA, Leclerc I. The AMP-regulated kinase family: enigmatic targets for diabetes therapy. Mol Cell Endocrinol. 2009;297(1–2):41–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care. 2001;24(3):489–94.Google Scholar
  7. 7.
    Lee YC, Asa SL, Drucker DJ. Glucagon gene 5′-flanking sequences direct expression of simian virus 40 large T antigen to the intestine, producing carcinoma of the large bowel in transgenic mice. J Biol Chem. 1992;267(15):10705–8.PubMedGoogle Scholar
  8. 8.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265–75.PubMedGoogle Scholar
  9. 9.
    Brubaker PL, Schloos J, Drucker DJ. Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line. Endocrinology. 1998;139(10):4108–14.PubMedCrossRefGoogle Scholar
  10. 10.
    Drucker DJ, Jin T, Asa SL, Young TA, Brubaker PL. Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line. Mol Endocrinol. 1994;8(12):1646–55.PubMedCrossRefGoogle Scholar
  11. 11.
    Gribble FM, Williams L, Simpson AK, Reimann F. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes. 2003;52(5):1147–54.PubMedCrossRefGoogle Scholar
  12. 12.
    Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med. 2005;11(1):90–4.Google Scholar
  13. 13.
    Kleinfeld AM, Prothro D, Brown DL, Davis RC, Richieri GV, DeMaria A. Increases in serum unbound free fatty acid levels following coronary angioplasty. Am J Cardiol. 1996;78(12):1350–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Shafrir E. Partition of unesterified fatty acids in normal and nephrotic syndrome serum and its effect on serum electrophoretic pattern. J Clin Invest. 1958;37(12):1775–82.PubMedCrossRefGoogle Scholar
  15. 15.
    Wu P, Yang L, Shen X. The relationship between GPR40 and lipotoxicity of the pancreatic beta-cells as well as the effect of pioglitazone. Biochem Biophys Res Commun. 2010;403(1):36–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Mishra R, Simonson MS. Saturated free fatty acids and apoptosis in microvascular mesangial cells: palmitate activates pro-apoptotic signaling involving caspase 9 and mitochondrial release of endonuclease G. Cardiovasc Diabetol. 2005;4(1):2.PubMedCrossRefGoogle Scholar
  17. 17.
    Saifer A, Goldman L. The free fatty acids bound to human serum albumin. J. Lipid Res. 1961;2(3):268–70.Google Scholar
  18. 18.
    Sheehan MT, Jensen MD. Metabolic complications of obesity. Pathophysiologic considerations. Med Clin North Am. 2000; 84(2): 363–85, vi.Google Scholar
  19. 19.
    Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science. 2000;288(5467):870–4.Google Scholar
  20. 20.
    Kim DS, Jeong SK, Kim HR, Kim DS, Chae SW, Chae HJ. Metformin regulates palmitate-induced apoptosis and ER stress response in HepG2 liver cells. Immunopharmacol Immunotoxicol. 2010; 32(2): 251–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Hinke SA, Martens GA, Cai Y, Finsi J, Heimberg H, Pipeleers D, et al. Methyl succinate antagonises biguanide-induced AMPK-activation and death of pancreatic beta-cells through restoration of mitochondrial electron transfer. Br J Pharmacol. 2007;150(8):1031–43.Google Scholar
  22. 22.
    Schulz E, Dopheide J, Schuhmacher S, Thomas SR, Chen K, Daiber A, et al. Suppression of the JNK pathway by induction of a metabolic stress response prevents vascular injury and dysfunction. Circulation. 2008;118(13):1347–57.Google Scholar
  23. 23.
    Xie Z, Dong Y, Scholz R, Neumann D, Zou MH. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation. 2008;117(7):952–62.PubMedCrossRefGoogle Scholar
  24. 24.
    Yi F, Sun J, Lim GE, Fantus IG, Brubaker PL, Jin T. Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinology. 2008;149(5):2341–51.PubMedCrossRefGoogle Scholar
  25. 25.
    Jin T. Why diabetes patients are more prone to the development of colon cancer? Med Hypotheses. 2008;71(2):241–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol. 2006;26(3):611–7.Google Scholar
  27. 27.
    Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30(5):359–71.PubMedCrossRefGoogle Scholar
  28. 28.
    Proctor WR, Bourdet DL, Thakker DR. Mechanisms underlying saturable intestinal absorption of metformin. Drug Metab Dispos. 2008;36(8):1650–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2012

Authors and Affiliations

  • Camilla Kappe
    • 1
  • Cesare Patrone
    • 1
  • Jens J. Holst
    • 2
  • Qimin Zhang
    • 1
  • Åke Sjöholm
    • 1
  1. 1.Department of Clinical Science and Education, Unit for Diabetes ResearchKarolinska InstitutetStockholmSweden
  2. 2.Department of Biomedical SciencesPanum InstituteCopenhagenDenmark

Personalised recommendations